Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IDEV vs GNTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IDEV Captures Overall Composite Edge (56.4 HOLD vs 35.3 SELL), While GNTA Leads 2–1 on Growth & Valuation Pillars

IDEV Overall Winner 6-Pillar Tally: IDEV 1 – 2 GNTA (3 Tie) Matrix Metrics: IDEV 3 – 5 GNTA

As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. IDEV trades at $88.40 (N/M Forward P/E, N/A operating margin) versus GNTA at $0.98 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IDEV is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1); meanwhile GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IDEV vs GNTA
IDEV NYSE Arca Head-to-Head Winner
iShares Core MSCI International Developed Markets ETF
Institutional Equity
$88.40
-1.43% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 19% Vol
Unified Composite Score
56.4 / 100 HOLD
Tech 48.0 Fund 50.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.6%) with fading momentum, RSI 44
RSI-14: 44.1 · SMA20: $89.47 · SMA50: $89.91
GNTA NASDAQ
Genenta Science S.p.A. American Depositary Shares
Biological Products, (No Diagnostic Substances)
$0.98
+20.62% 1D
Market Cap $39.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.45β · 132% Vol
Unified Composite Score
35.3 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.6 · SMA20: $0.69 · SMA50: $0.78

6-Pillar Scorecard Institutional Category Breakdown (IDEV 1 – 2 GNTA)

Columns: Metric · IDEV · GNTA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale GNTA
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $39.4M
3. Profitability & Quality GNTA
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -38.0%
4. Balance Sheet & Cash Flow IDEV
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $1.05 Book/Sh · -38.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 26.3% (11th %ile) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IDEV (3) vs GNTA (5)
Institutional Metric IDEV GNTA Criterion Row Edge
Market Capitalization
Scale
N/A $39.4M Larger Scale GNTA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth GNTA
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin GNTA
Net Profit Margin
Profitability
N/A 0.0% Higher Margin GNTA
Return on Equity (ROE)
Capital Efficiency
N/A -38.0% Higher ROE GNTA
52-Week Range Position
Momentum
65% ($78–$94) 18% ($1–$3) Stronger Trend IDEV
Beta / 30D Volatility
Risk Regime
0.94β · 19% Vol 1.45β · 132% Vol Lower Realized Risk IDEV
Unified Institutional Score
Composite Signal
56.4 / 100 (HOLD) 35.3 / 100 (SELL) Higher Composite IDEV
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($1.05 Book/Sh · -38.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GNTA +35.67 pp
IDEV: -0.74% · GNTA: +34.93%
3M Horizon IDEV +22.31 pp
IDEV: -3.63% · GNTA: -25.94%
6M Horizon GNTA +45.93 pp
IDEV: +1.08% · GNTA: +47.01%
1Y Horizon IDEV +64.14 pp
IDEV: +9.32% · GNTA: -54.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDEV vs GNTA. Trailing 12-month operating profitability (IDEV N/A vs GNTA 0.0%) and valuation multiples (IDEV N/M vs GNTA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IDEV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
GNTA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-38.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IDEV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 26.3%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IDEV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GNTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IDEV Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GNTA Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $39.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IDEV vs GNTA Key Questions & Quantitative Answers

As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. IDEV trades at $88.40 (N/M Forward P/E, N/A operating margin) versus GNTA at $0.98 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IDEV is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1); meanwhile GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GNTA leads the Growth & Scale pillar: IDEV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GNTA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IDEV generates N/A in USD-normalized revenue versus N/A for GNTA. In operating R&D and SG&A reinvestment, IDEV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNTA.

IDEV and GNTA trade at balanced relative valuation multiples. IDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GNTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IDEV (N/A ROE) versus GNTA (-38.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IDEV carries 26.3% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 19% Vol realized risk). By comparison, GNTA carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 132% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

iShares Core MSCI International Developed Markets ETF (IDEV) Research Suite

Genenta Science S.p.A. American Depositary Shares (GNTA) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.